Goldman Sachs Group, Inc. (The) restated their sell rating on shares of Celgene Corporation (NASDAQ:CELG) in a research note released on Friday, October 27th. They currently have a $91.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $116.00.
Several other equities research analysts also recently issued reports on CELG. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $175.00 price objective on shares of Celgene Corporation in a research note on Wednesday, August 9th. Vetr raised shares of Celgene Corporation from a buy rating to a strong-buy rating and set a $148.32 target price on the stock in a research report on Wednesday, August 16th. Cantor Fitzgerald reissued a buy rating and set a $162.00 target price on shares of Celgene Corporation in a research report on Tuesday, September 26th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $150.00 price target on shares of Celgene Corporation in a report on Friday, July 14th. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of Buy and an average price target of $139.64.
Shares of Celgene Corporation (CELG) opened at $102.34 on Friday. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The stock has a market cap of $80,574.02, a P/E ratio of 15.99, a P/E/G ratio of 0.79 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. equities analysts anticipate that Celgene Corporation will post 6.67 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Celgene Corporation (CELG) Given Sell Rating at Goldman Sachs Group, Inc. (The)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/goldman-sachs-group-inc-the-reaffirms-sell-rating-for-celgene-corporation-celg.html.
In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now directly owns 9,250 shares of the company’s stock, valued at $1,286,027.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of CELG. Thompson Davis & CO. Inc. lifted its holdings in shares of Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI lifted its holdings in shares of Celgene Corporation by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the period. Robecosam AG bought a new position in shares of Celgene Corporation during the third quarter valued at $114,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Celgene Corporation in the first quarter valued at $118,000. Finally, Guidant Wealth Advisors acquired a new stake in shares of Celgene Corporation in the third quarter valued at $119,000. 78.92% of the stock is owned by institutional investors.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.